A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel

European Journal of Contraception and Reproductive Health Care

Volumn 7, Issue 2, 2002, Pages 79-90

  Endrikat, J ^a   Blode, H ^a   Gerlinger, C ^a   Rosenbaum, P ^a   Kuhnz, W ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Ethinylestradiol; Levonorgestrel; Oral contraceptives; Pharmacokinetics

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRANSCORTIN; PROGESTERONE DERIVATIVE; SERUM ALBUMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; MASTALGIA; ORAL CONTRACEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; HALF LIFE TIME; LIVER; METABOLISM; TIME;

ADULT; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHINYL ESTRADIOL; FEMALE; HALF-LIFE; HUMANS; LEVONORGESTREL; LIVER; PROGESTERONE CONGENERS; SERUM ALBUMIN; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME FACTORS;

EID: 0036323046     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/ejc.7.2.79.90     Document Type: Article

References (18)

1. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose mnophasic oral contraceptive containing gestodene
2. German trial of an oral contraceptive containing 0.150 mg desogestrel plus 0.020 mg ethinylestradiol
3. A review of 'once a month' combined injectable contraceptives
4. Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinylestradiol
5. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel over six treatment cycles
6. Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova®) in Germany
7. The relative bioavailability of levonorgestrel and ethinylestradiol administered as a low-dose combination oral contraceptive
8. The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form
9. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women
10. Levonorgestrel clinical pharmacokinetics
11. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation
12. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of levonorgestrel and influence on free and total testosterone levels in serum
13. Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroids levonorgestrel, 3-ketodesogestrel and gestodene
14. Radioimmunological analysis of ethinylestradiol in human serum
15. Distribution and percentages of non-protein bound contraceptive steroids in human serum
16. The pharmacokinetics of levonorgestrel and ethinylestradiol in women - Studies with ovran and ovranette
17. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy